Allworth Financial LP raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 8.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 323,363 shares of the company's stock after acquiring an additional 26,459 shares during the quarter. Allworth Financial LP's holdings in Johnson & Johnson were worth $46,975,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Knuff & Co LLC lifted its stake in Johnson & Johnson by 0.7% during the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company's stock valued at $1,534,000 after acquiring an additional 64 shares during the period. Vertex Planning Partners LLC lifted its stake in Johnson & Johnson by 1.3% during the 3rd quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company's stock valued at $844,000 after acquiring an additional 65 shares during the period. Freedom Day Solutions LLC lifted its stake in Johnson & Johnson by 1.1% during the 3rd quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company's stock valued at $1,016,000 after acquiring an additional 66 shares during the period. Traphagen Investment Advisors LLC lifted its stake in shares of Johnson & Johnson by 0.6% in the 3rd quarter. Traphagen Investment Advisors LLC now owns 10,483 shares of the company's stock valued at $1,699,000 after purchasing an additional 67 shares during the period. Finally, Corepath Wealth Partners LLC lifted its stake in shares of Johnson & Johnson by 3.7% in the 4th quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company's stock valued at $287,000 after purchasing an additional 70 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.
Wall Street Analyst Weigh In
Several research firms recently issued reports on JNJ. Royal Bank of Canada reiterated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday. Guggenheim boosted their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a "neutral" rating in a research note on Monday, February 3rd. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Stifel Nicolaus decreased their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research note on Thursday, January 23rd. Finally, Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $170.67.
View Our Latest Stock Analysis on JNJ
Johnson & Johnson Trading Up 1.7 %
Shares of JNJ traded up $2.67 during mid-day trading on Friday, reaching $162.35. The stock had a trading volume of 12,540,171 shares, compared to its average volume of 9,073,381. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The business's fifty day moving average is $148.61 and its 200 day moving average is $155.89. The firm has a market cap of $390.87 billion, a price-to-earnings ratio of 24.41, a P/E/G ratio of 2.53 and a beta of 0.52.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the prior year, the firm posted $2.29 earnings per share. Johnson & Johnson's quarterly revenue was up 5.3% on a year-over-year basis. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.06%. Johnson & Johnson's payout ratio is currently 74.59%.
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark A. Weinberger purchased 1,000 shares of the firm's stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company's stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is owned by insiders.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
